Featured Content |view more
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.
Why test the combination of Trodelvy and pembrolizumab?
Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, ...
The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber ...
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at ...
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.
Receive updates about Dana-Farber's advances in cancer research and care, current clinical trials, and upcoming CME programs.
- Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial